Rabbit Models for Alzheimer's Disease

submitted by: alex01

Diana Woodruff-Pak (Temple University, Philadelphia, PA) used cholesterol-fed rabbits as a model of AD for evaluation of currently available and potential anti-Alzheimer drugs. These animals developed typical Alzheimer pathology, including behavioral changes and deposition of ß-amyloid and even
tau. Galantamine and donepezil partially protected animals from Alzheimer symptomatology.

TGFß & Alzheimer's Disease

submitted by: alex01

R.A. Flavell (Yale University, New Haven, CT) discusses the role of Transforming Growth Factor ß (TGFß) in disease. In the central nervous system of a murine model of AD this cytokine appears to prevent macrophages from attacking ß-amyloid. Flavell visualizes that selective blockade of this TGFß
activity could lead to the destruction of plaques in patients with AD.

Neuropathic Pain Neurodegenerative Disease

submitted by: alex01

Dr. Remi Quirion (McGill University, Montreal, Quebec, Canada) described enhancement of the effects of pain-related peptides by PGE2 . This finding suggests a new, possible complimentary approach to the therapy of pain. Qurion also discussed anti-Alzheimer effect of polyphenols. This effect appears to be due not due to their antioxidant activity only. Quirion suggested the existence of membrane protein than binds polyphenols.

Cannabinoids

submitted by: alex01
Daniele Piomelli, PhD. - Another approach was discussed by D. Piomelli (University of California, Irvine). URB 597, an inhibitor of fatty acid amide hydrolase (FAAH), is expected to increase anandamide signaling and is being currently clinically tested in the therapy of pain. An increase in anandamide signaling may also be useful in the therapy of depression. This is a novel approach to the development of antidepressants. The signaling can be enhanced by blocking anadamide metabolism or by...

Drug Discovery for Alzheimer's Disease

submitted by: alex01

Gregory Rose from PharmExperts.com interviews J. Buccafusco (Medical College of Georgia, Augusta, GA) about his development of new anti-Altzheimer drugs, designed to act by multiple mechanisms to improve congnition. Desensitization of nicotinic receptors is one of the novel approaches proposed by Buccafusco. Three of his compounds are currently in advanced preclinical evaluation.